Asian Currencies Rise as Yen Surges on Fed Rate Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
JPMorgan Sees ECB Raising Rates to 2.75% in December 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
U.S. Payrolls Seen Rebounding in August as Labor Market Stays Soft 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Trump Signs Order to Cut Routine Childhood Vaccines 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Add as a preferred source on Google
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
